
1. annu rev pharmacol toxicol. 2017 jan 6;57:329-348. doi:
10.1146/annurev-pharmtox-010716-105055. epub 2016 dec 7.

will cure ebola?

cardile ap(1), warren tk(1), martins ka(1), reisler rb(1), bavari s(1).

author information: 
(1)us army medical research institute infectious diseases, frederick, maryland
21702; email: anthony.p.cardile.mil@mail.mil.

despite unprecedented ebola virus outbreak response west africa, ebola 
medical countermeasures approved us food drug
administration. however, multiple valuable lessons learned the
conduct clinical research resource-poor, high risk-pathogen setting.
numerous therapeutics explored developed outbreak, including
repurposed drugs, nucleoside nucleotide analogues (bcx4430, brincidofovir,
favipiravir, gs-5734), nucleic acid-based drugs (tkm-ebola avi-7537), and
immunotherapeutics (convalescent plasma zmapp). review ebola therapeutics 
progress aftermath west africa ebola virus outbreak attempt 
offer glimpse path forward.

doi: 10.1146/annurev-pharmtox-010716-105055 
pmid: 27959624  [indexed medline]

